In vivo BCMA-CAR T therapy delivered by a single IV treatment for multiple myeloma
Official title: Off-the-shelf in vivo CAR-T therapy for multiple myeloma
Funded at Vyriad, INC. · NIH-11410209 · Data updated 2026-11-12
A new therapy aims to generate CAR-T cells directly inside the patient’s body to treat multiple myeloma, potentially reducing wait times and procedure costs.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vyriad, INC. NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | September 7, 2026 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,044,729 |
| NIH project number | 1R44CA314911-01 |
| Project ID | NIH-11410209 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with multiple myeloma eligible for BCMA-targeted therapy who meet safety criteria for a first-in-human trial.
✕Less likely to help
Patients not eligible for CAR-T therapy or who have contraindications to viral vector-based approaches may not benefit.
What this research studies
This program explores an off-the-shelf approach that injects a special viral vector into a patient to turn their own T cells into cancer-fighting CAR-T cells against BCMA, a protein on myeloma cells. It builds on prior lab and animal work showing the approach can create functional CAR-T cells without traditional apheresis or hospital-based manufacturing. If successful, patients might receive treatment faster and with less upfront chemotherapy. The grant funds early phase clinical testing to assess safety and preliminary effectiveness in people with multiple myeloma.
Why it matters
Potential benefit: If successful, patients could access CAR-T therapy more quickly and potentially at lower cost.
How similar studies have gone: Preclinical data and early in vivo work suggest this approach can generate functional CAR-T cells and reduce tumor burden in models.
Where this research is happening
-
Vyriad, INC.
Rochester, United States Active
Researchers
- Principal investigator: Russell, Luke O. — Vyriad, INC.
- Study coordinator: Russell, Luke O.
Related research
Other NIH-funded projects on the same topics.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
-
How LDL Affects Multiple Myeloma: New Pathways to Keep Remission
A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.
-
Therapy-induced senescence and immune activation in multiple myeloma
A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.
-
BCMA CAR-T enteritis: understanding immune toxicities in multiple myeloma
A broad study to uncover why some CAR-T cell treatments targeting BCMA cause severe intestinal inflammation in people with multiple myeloma.
-
Understanding Drug-Resistant Multiple Myeloma to Stop Relapse
Researchers are studying why some myeloma cells resist treatment and how to create new therapies to prevent relapse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.